top of page

PUBLICATIONS FROM THE LAB

Several Open Books

  1. Valeri E, Breggion S, Barzaghi F, Abou Alezz M, Crivicich G, Pagani I, Forneris F, Sartirana C, Costantini M, Costi S, Marino A, Chiarotto E, Colavito D, Cimaz R, Merelli I, Vicenzi E, Aiuti A, Kajaste-Rudnitski A. A novel STING variant triggers endothelial toxicity and SAVI disease. J Exp Med. 2024 Sep 2;221(9):e20232167.

  2. Gyrd-Hansen M, Kajaste-Rudnitski A, Manel N, Rehwinkel J, van der Veen AG, Iannacone M. Advancements in pathogen immunity and signaling. Nat Immunol. 2024 Aug;25(8):1322-1325.

  3. Valeri E, Unali G, Piras F, Abou-Alezz M, Pais G, Benedicenti F, Lidonnici MR, Cuccovillo I, Castiglioni I, Arévalo S, Spinozzi G, Merelli I, Behrendt R, Oo A, Kim B, Landau NR, Ferrari G, Montini E, Kajaste-Rudnitski A. Removal of innate immune barriers allows efficient transduction of quiescent human hematopoietic stem cells. Mol Ther. 2024 Jan 3;32(1):124-139.

  4. Kerzel T, Giacca G, Beretta S, Bresesti C, Notaro M, Scotti MG, Balestrieri C, Canu T, Redegalli M, Pedica F, Genua M, Ostuni R, Kajaste-Rudnitski A, Oshima M, Tonon G, Merelli I, Aldrighetti L, Dellabona P, Coltella N, Doglioni C, Rancoita PMV, Sanvito F, Naldini L, Squadrito LM. In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases. Cancer Cell, 2023 Nov 13;41(11):1892-1910.e10.

  5. Costa-Verdera H, Unzu C, Valeri E, Adriouch S, Gonzalez-Aseguinolaza G, Mingozzi F, Kajaste-Rudnitski A. Understanding and tackling immune responses to AAV vectors. Hum Gene Ther. 2023 Sep 6. doi: 10.1089/hum.2023.119.

  6. Colantuoni M, Jofra Hernandez R, Pettinato E, Basso-Ricci L, Magnani L, Andolfi G, Rigamonti C, Finardi A, Romeo V, Soldi M, Sergi Sergi L, Rocchi M, Scala S, Hoffman HM, Gregori S, Kajaste-Rudnitski A, Sanvito F, Muzio L, Naldini L, Aiuti A, Mortellaro A. Constitutive IL-1RA production by modified immune cells protects against IL-1-mediated inflammatory disorders. Sci Transl Med. 2023 May 31;15(698):eade3856.

  7. Ferrari S, Valeri E, Conti A, Scala S, Aprile A, Di Micco R, Kajaste-Rudnitski A, Montini E, Ferrari G, Aiuti A, Naldini L. Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy. Cell Stem Cell. 2023 May 4;30(5):549-570.

  8. Unali G, Crivicich G, Pagani I, Abou-Alezz M, Folchini F, Valeri E, Matafora V, Reisz JA, Giordano AMS, Cuccovillo I, Butta GM, Donnici L, D'Alessandro A, De Francesco R, Manganaro L, Cittaro D, Merelli I, Petrillo C, Bachi A, Vicenzi E, Kajaste-Rudnitski A. Interferon-inducible phospholipids govern IFITM3-dependent endosomal antiviral immunity. EMBO J. 2023 Mar 27:e112234.

  9. Giordano AMS, Abou Alezz M, Merelli I, Kajaste-Rudnitski A. Protocol to differentiate monolayer human induced pluripotent stem cells into inflammatory responsive astrocytes. STAR Protoc. 2023 Mar 6;4(1):102142.

  10. Kajaste-Rudnitski A and Aiuti A. Towards improved, yet regulated gene therapy for X-CGD. Blood. 2023 Mar 2;141(9):966-967.

  11. Ferrari S, Jacob A, Cesana D, Laugel M, Beretta S, Varesi A, Unali G, Conti A, Canarutto D, Albano L, Calabria A, Vavassori V, Cipriani C, Castiello MC, Esposito S, Brombin C, Cugnata F, Adjla O, Ayuso E, Merelli I, Villa A, Di Micco R, Kajaste-Rudnitski A, Montini E, Penaud-Budloo M, Naldini L. Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells. Cell Stem Cell 2022 Oct 6;29(10):1428-1444.e9.

  12. Giordano AMS, Luciani M, Gatto F, Abou Alezz M, Beghè C, della Volpe L, Migliara A, Valsoni S, Genua M, Dzieciatkowska M, Frati G, Tahraoui-Bories J, Giliani S, Orcesi S, Fazzi E, Ostuni R, D’Alessandro A, Di Micco R, Merelli I, Lombardo A, Reijns MAM, Gromak N, Gritti A, Kajaste-Rudnitski A*. DNA damage contributes to neurotoxic inflammation in Aicardi-Goutières Syndrome astrocytes. J Exp Med. 2022 Apr 4;219(4):e20211121. * Senior and corresponding author.

  13. Molteni R, Biavasco R, Stefanoni D, Nemkov T, Domínguez-Andrés J, Arts RJ, Merelli I, Mazza D, Zambrano S, Panigada M, Cantoni E, Tengesdal I, Maksud P, Piras F, Cesana D, Cassina L, Distefano G, Loffreda A, Gnani D, De Luca G, Tomelleri A, Campochiaro C, Joosten LAB, Dinarello CA, Kajaste-Rudnitski A, Haroche J, Cardaci S, Cenci S, Dagna L, Doglioni C, Ferrarini M, Ferrero E, Boletta A, D’Alessandro A, Montini E, Netea M, Giulio Cavalli. Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. Blood. 2021 Oct 28;138(17):1554-1569.

  14. Unali G, Giordano AMS, Cuccovillo I, Abou Alezz M, Apolonia L, Merelli I, Malim MH, C. Petrillo C, Kajaste-Rudnitski A*. The lysine-rich intracellular loop and cell type-specific co-factors are required for IFITM3 antiviral immunity in hematopoietic stem cells. bioRxiv 2021.04.06.438585. * Senior and corresponding author.

  15. Torretta S, Scagliola A, Ricci L, Mainini F, Di Marco S, Cuccovillo I, Kajaste-Rudnitski A, Sumpton D, Ryan KM, Cardaci S. D-mannose suppresses macrophage IL-1β production. Nat Commun. 2020 Dec 11;11(1):6343.

  16. Soldi M, Sergi Sergi L, Unali G, Kerzel T, Cuccovillo I, Capasso P, Annoni A, Biffi M, Rancoita PMV, Cantore A, Lombardo A, Naldini L, Squadrito ML, Kajaste-Rudnitski A. Laboratory-Scale Lentiviral Vector Production and Purification for Enhanced Ex Vivo and In Vivo Genetic Engineering. Mol Ther Methods Clin Dev. 2020 Oct 20;19:411-425. * Senior and corresponding author.

  17. Piras F and Kajaste-Rudnitski A*. Antiviral immunity and nucleic acid sensing in haematopoietic stem cell gene engineering. Gene Ther. 2020 Jul 13:1-13. * Senior and corresponding author.

  18. Comi M, Amodio G, Passeri L, Fortunato M, Santoni De Sio F, Andolfi G, Kajaste-Rudnitski A, Russo F, Cesana L, Gregori S. Generation of powerful human tolerogenic dendritic cells by lentiviral-mediated IL-10 gene transfer. Front Immunol. 2020 Jun 30;11:1260.

  19. Ferrari S, Jacob A, Beretta S, Unali G, Albano L, Vavassori V, Cittaro D, Lazarevic D, Brombin C, Cugnata F, Kajaste-Rudnitski A, Merelli I, Genovese P, Naldini L. Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. Nat Biotechnol. 2020 Jun 29.

  20. Petrillo C, Calabria A, Piras F, Capotondo A, Spinozzi G, Cuccovillo I, Benedicenti F, Naldini L, Montini E, Biffi A, Gentner B, Kajaste-Rudnitski A*. Assessing the impact of Cyclosporine A on lentiviral transduction and preservation of human hematopoietic stem cells in clinically relevant ex-vivo gene therapy settings. Hum Gene Ther. 2019 Apr 30. * Senior and corresponding author.

  21. Petrillo C, Thorne LG, Unali G, Schiroli G, Giordano AMS, Piras F, Cuccovillo I, Petit SJ, Ahsan F, Noursadeghi M, Clare BS, Genovese P, Gentner B, Cittaro D, Naldini L, Towers GJ, Kajaste-Rudnitski A*. Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. Cell Stem Cell. 2018 Dec 6;23(6):820-832.e9. * Senior and corresponding author. Recommended in F1000Prime as being of special significance in its field.

  22. Piras F, Riba M, Petrillo C, Lazarevic D, Cuccovillo I, Bartolaccini S, Stupka E, Gentner B, Cittaro D, Naldini L, Kajaste-Rudnitski A*. Lentiviral Vectors Escape Innate Sensing but Trigger p53 In Human Hematopoietic Stem and Progenitor Cells. EMBO Mol Med. Sep;9(9):1198-1211. 2017. * Senior and corresponding author

  23. Zonari E, Desantis G, Petrillo C, Boccalatte FE, Lidonnici MR, Kajaste-Rudnitski A, Aiuti A, Ferrari G, Naldini L, Gentner B. Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy. Stem Cell Reports. Apr 11;8(4):977-990. 2017.

  24. Turrini F, Marelli S, Kajaste-Rudnitski A, Lusic M, Van Lint C, Das AT, Harwig A, Berkhout B, Vicenzi E. HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter. Retrovirology. Dec 18;12(1):104. 2015.

  25. Kajaste-Rudnitski A*. and Naldini L., Cellular innate immunity and restriction of viral infection - implications for lentiviral gene therapy in human hematopoietic cells. Hum Gene Ther. Apr;26(4):201-9. 2015. * Senior and corresponding author

  26. Petrillo C, Cesana D, Piras F, Bartolaccini S, Naldini L, Montini E, Kajaste-Rudnitski A*. Cyclosporin A and Rapamycin relieve distinct lentiviral restriction blocks in hematopoietic stem and progenitor cells. Mol Ther., Feb. 23. 2015. * Senior and corresponding author

  27. Chiriaco M, Farinelli G, Capo V, Zonari E, Scaramuzza S, Di Matteo G, Sergi LS, Migliavacca M, Hernandez RJ, Bombelli F, Giorda E, Kajaste-Rudnitski A, Trono D, Grez M, Rossi P, Finocchi A, Naldini L, Gentner B, Aiuti A. Dual-Regulated Lentiviral Vector for Gene Therapy of X-linked Chronic Granulomatosis. Mol Ther., May 29. 2014.

  28. Escobar G., Moi D., Ranghetti A., Ozkal-Baydin P., Squadrito ML., Kajaste-Rudnitski A., Bondanza A., B. Gentner B., De Palma M., Mazzieri R. and Naldini L. Genetic Engineering of Hematopoiesis for Targeted IFN-α Delivery Inhibits Breast Cancer Progression. Sci Transl Med., Jan 1;6(217):217. 2014.

  29. Ghezzi S, Galli L, Kajaste-Rudnitski A, Turrini F, Marelli S, Toniolo D, Casoli C, Riva A, Poli G, Castagna A and Vicenzi E. Identification of TRIM22 Single Nucleotide Polymorphisms Associated with Loss of Inhibition of HIV-1 Transcription and Advanced HIV-1 Disease. AIDS., Sep 24;27(15):2335-44. 2013.

  30. Pezzoli D., Kajaste-Rudnitski A., Chiesa R., Candiani G., Lipid-based nanoparticles as non-viral gene delivery vectors. Methods Mol Biol., 1025:269-79. 2013.

  31. Cassetta L, Kajaste-Rudnitski A, Coradin T, Della Chiara G, Barbagallo M, Saba S, Alfano M, Cassol E, Vicenzi E and Guido Poli. M1 Polarization of Human Monocyte-Derived Macrophages Restricts Pre- and Post-Integration Steps of HIV-1 Replication. AIDS. Jul 31;27(12):1847-56. 2013.

  32. Di Pietro A.*, Kajaste-Rudnitski A.*, Oteiza A., Nicora L., Towers GJ., Mechti N., Vicenzi E. TRIM22 Inhibits Influenza A Virus Infection by Targeting the Viral Nucleoprotein for Degradation. J Virol., Apr;87(8):4523-33. 2013.  *shared first authorship

  33. Mascagni P, Vicenzi E, Kajaste-Rudnitski A, Pellicciotta G, Monti A, Cervi C, Vitalucci R, Toffoletto F. Assessment of efficacy and safety of pandemic A/H1N1/2009 influenza vaccine in a group of health care workers. Med. Lav., May 103(3): 220-29. 2012.

  34. Mariani SA, Brigida I, Kajaste-Rudnitski A, Ghezzi S, Rocchi A, Plebani A, Vicenzi E, Aiuti A & Guido Poli G. HIV-1 Envelope Dependent Restriction of CXCR4-Using Viruses in Children But Not Adult Untransformed CD4+ T Lymphocyte Lines. Blood., Mar 1;119(9):2013-23. 2012.

  35. Kajaste-Rudnitski A*, Marelli S, Pultrone C, Pertel T, Mechti N, Poli G, Luban J, Vicenzi E. TRIM22 Inhibits HIV-1 Transcription Independently of Its E3-Ubiquitin Ligase Activity, Tat and NF-{kappa}cB Responsive LTR Elements. J Virol., May;85(10):5183-96. 2011. *corresponding authorship

  36. Kajaste-Rudnitski A, Galli L, Nozza S, Tambussi G, Di Pietro A, Pellicciotta G, Monti A, Mascagni P, Moro M, Vicenzi E. Induction of Protective Antibody Response by MF59-Adjuvanted 2009 Pandemic A/ H1N1v Influenza Vaccine in HIV-1 Infected Individuals. AIDS, Jan 14;25(2):177-83. 2011.

  37. Mertens E, Kajaste-Rudnitski A, Torres S, Funk A, Frenkiel MP, Iteman I, Khromykh AA, Desprès P. Viral determinants in the NS3 helicase and 2K peptide that promote West Nile virus resistance to antiviral action of 2',5'-oligoadenylate synthetase 1b. Virology, 30;399(1):176-85. Mar. 2010.

  38. Kajaste-Rudnitski A, Pultrone C, Marzetta F, Ghezzi S, Coradin T, Vicenzi E. Restriction factors of retroviral replication: the example of Tripartite Motif (TRIM) protein 5alpha and 22. Amino Acids. 39(1):1-9, Jun. 2010.

  39. Capua I, Kajaste-Rudnitski A, Bertoli E, Vicenzi E. Pandemic vaccine preparedness- have we left something behind? Plos Pathogens, Nov. 2009.

  40. Pinna D, Oreste P, Coradin T, Kajaste-Rudnitski A, Ghezzi S, Zoppetti G, Rotola A, Argnani R, Poli G, Manservigi R, Vicenzi E. Inhibition of Herpes Simplex Virus Type 1 and 2 in vitro Infection by Sulfated Derivatives of K5 Escherichia Coli Polysaccharide. Antimicrob Agents Chemother. 52:3078-84, 2008.

  41. Candiani G, Pezzoli D, Cabras M, Ristori S, Pellegrini C, Kajaste-Rudnitski A, Vicenzi E, Sala C, Zanda M. A dimerizable cationic lipid with potential for gene Delivery. J Gene Med. 10: 637-645, 2008.

  42. Kajaste-Rudnitski A, Mashimo T, Frenkiel MP, Guenet JL, Lucas M, & Despres P. The 2',5' oligoadenylate synthetase 1b is a potent inhibitor of West Nile virus replication inside infected cells. J Biol Chem. 281:4624-37, 2006.

  43. Sakuntabhai, C. Turbpaiboon, I. Casadémont, A. Chuansumrit, T. Lowhnoo, A. Kajaste-Rudnitski, S.M. Kalayanarooj,K. Tangnararatchakit, N. Tangthawornchaikul, S. Vasanawathana, W. Chaiyaratana, P. Yenchitsomanus, P. Suriyaphol, P. Avirutnan, K. Chokephaibulkit, F. Matsuda, S. Yoksan,  Y. Jacob, M. Lathrop, P. Malasit, P. Desprès, & C. Julier: A variant located in the promoter of the CD209 (DC-SIGN) gene is associated with the severity of dengue disease. Nat Genet. 37:507-13, 2005.     

bottom of page